← All trials
NCT01578213
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2011
- Primary completion
- Nov 1, 2018
- Completion date
- May 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of MilanLead sponsor
- Azienda Ospedaliero-Universitaria Policlinico - Vittorio EmanueleOverall official - principal investigator
- A.O. Bianchi-Melacrino-MorelliOverall official - principal investigator
- Ospedale S. BortoloOverall official - principal investigator
- University of MilanOverall official - principal investigator
- Vita-Salute University of Milano. ItalyOverall official - principal investigator
- McGill UniversityOverall official - principal investigator
- Tel Aviv UniversityOverall official - principal investigator
- Azienda Ospedaliera San Gerardo di MonzaStudy director
- University of ZaragozaOverall official - principal investigator
- Onze Lieve Vrouw HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.